Benjamin Looker Biography and Net Worth

General Counsel of Esperion Therapeutics

Mr. Looker began his legal career as a corporate lawyer at Goodwin Procter LLP and joins Esperion most recently from Trillium Therapeutics, where he served on the executive team as the company’s first general counsel, managing all of the company’s legal matters, including corporate governance and SEC compliance, risk management and intellectual property asset protection, until the company’s acquisition by Pfizer Inc. in November 2021. Prior to Trillium Therapeutics, he served as Vice President, Head of U.S. Legal and Global Business Operations for MorphoSys US Inc., a commercial-stage biopharmaceutical company where he provided guidance on multiple business initiatives, including sales and marketing activities, business development, corporate structure, the enforcement environment and risk mitigation strategies. Prior to MorphoSys, Mr. Looker held legal roles of increasing responsibility at EMD Serono, Inc., a U.S. subsidiary of Merck KGaA Darmstadt, Germany.

Mr. Looker received his B.S. degree in finance and management information systems from Boston College and his J.D. from Boston College Law School.

What is Benjamin Looker's net worth?: The estimated net worth of Benjamin Looker is at least $1.49 million as of September 17th, 2025. Looker owns 393,670 shares of Esperion Therapeutics stock worth more than $1,492,009 as of December 5th. This net worth estimate does not reflect any other investments that Looker may own. Additionally, Looker receives a salary of $550,350.00 as General Counsel at Esperion Therapeutics. Learn More about Benjamin Looker's net worth.
How old is Benjamin Looker?: Looker is currently 42 years old. There are 4 older executives and no younger executives at Esperion Therapeutics. The oldest executive at Esperion Therapeutics is Mr. Glenn P. Brame, Chief Technical Operations Officer, who is 66 years old. Learn More on Benjamin Looker's age.
What is Benjamin Looker's salary?: As the General Counsel of Esperion Therapeutics, Inc., Looker earns $550,350.00 per year. There are 2 executives that earn more than Looker. The highest earning executive at Esperion Therapeutics is Mr. Sheldon L. Koenig, President, CEO & Director, who commands a salary of $1,280,000.00 per year. Learn More on Benjamin Looker's salary.
How do I contact Benjamin Looker?: The corporate mailing address for Looker and other Esperion Therapeutics executives is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. Esperion Therapeutics can also be reached via phone at (734) 887-3903 and via email at [email protected]. Learn More on Benjamin Looker's contact information.
Has Benjamin Looker been buying or selling shares of Esperion Therapeutics?: Benjamin Looker has not been actively trading shares of Esperion Therapeutics during the past quarter. Most recently, Benjamin Looker sold 6,267 shares of the business's stock in a transaction on Wednesday, September 17th. The shares were sold at an average price of $2.80, for a transaction totalling $17,547.60. Following the completion of the sale, the general counsel now directly owns 393,670 shares of the company's stock, valued at $1,102,276. Learn More on Benjamin Looker's trading history.
Who are Esperion Therapeutics' active insiders?: Esperion Therapeutics' insider roster includes Benjamin Halladay (CFO), and Benjamin Looker (General Counsel). Learn More on Esperion Therapeutics' active insiders.
Are insiders buying or selling shares of Esperion Therapeutics?: In the last year, insiders at the biopharmaceutical company sold shares 10 times. They sold a total of 31,842 shares worth more than $59,811.61. The most recent insider tranaction occured on September, 17th when General Counsel Benjamin Looker sold 6,267 shares worth more than $17,547.60. Insiders at Esperion Therapeutics own 1.7% of the company. Learn More about insider trades at Esperion Therapeutics.
Information on this page was last updated on 9/17/2025.

Benjamin Looker Insider Trading History at Esperion Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/17/2025	Sell	6,267	$2.80	$17,547.60	393,670
7/17/2025	Sell	1,304	$1.13	$1,473.52	399,937
6/17/2025	Sell	6,422	$1.15	$7,385.30	401,241
4/19/2023	Sell	1,290	$1.27	$1,638.30	83,663
1/18/2023	Sell	6,347	$7.00	$44,429.00	64,453

Benjamin Looker Buying and Selling Activity at Esperion Therapeutics

Esperion Therapeutics Company Overview

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Today's Range

Now: $3.79

$3.76

$3.91

50 Day Range

MA: $2.99

$2.45

$4.00

2 Week Range

Now: $3.79

$0.69

$4.03

Volume

4,725,351 shs

Average Volume

7,200,330 shs

Market Capitalization

$906.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.01

Benjamin Looker Biography and Net Worth

What is Benjamin Looker's net worth?

How old is Benjamin Looker?

What is Benjamin Looker's salary?

How do I contact Benjamin Looker?

Has Benjamin Looker been buying or selling shares of Esperion Therapeutics?

Who are Esperion Therapeutics' active insiders?

Are insiders buying or selling shares of Esperion Therapeutics?